Dose optimisation for Loss of Response to Vedolizumab— Pharmacokinetics and Immune Mechanisms
- 10 April 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (10) , 1707-1719
Abstract
Real life data regarding pharmacokinetics of vedolizumab in patients needing dose optimisation are scarce. We set to examine whether pre-optimisation vedolizumab levels associate with therapy outcomes and which mechanisms explain the associations. A multicentre observational study assessed the outcome of dose increase in association with pre-escalation levels in vedolizumab-treated patients. SubsequentIy, α4β7 occupancy on peripheral blood [PB] and intestinal lamina propria [LP] tissues was investigated on various cellular subsets in patients undergoing lower endoscopy on infusion day. Cellular localisation of vedolizumab-bound α4β7 and effects on M1 and M2 macrophages were also explored. A total of 161 inflammatory bowel disease [IBD] patients were included. Among 129/161 patients intensified during maintenance [Week 14 onward], pre-intensification trough levels were comparable or higher among those subsequently attaining post-optimisation clinical, biomarker, and endoscopic remission, compared with non-remitting patients [p = 0.09, 0.25, 0.04, respectively]. Similar results were demonstrated for those dose-optimised during induction [Week 6, n = 32]. In the immune sub-study [n = 43], free α4β7 receptors at trough were similarly low among patients with/without mucosal healing, on PB T cells [p = 0.15], LP T cells [p = 0.88], and on PB eosinophils [p = 0.08]. Integrin receptors on M1 and M2 macrophages were also saturated by low levels of vedolizumab and anti-inflammatory cytokine secretion was not increased. Co-localisation and dissociation experiments demonstrated membranal α4β7 receptors of two origins: non-internalised and newly generated α4β7, but re-binding was still complete at very low concentrations. These results do not support pharmacokinetics as the mechanism responsible for loss of response to vedolizumab, nor do they support a need for higher drug concentration to enhance vedolizumab’s immune effects. Higher pre-escalation levels may indicate less clearance [less severe disease] and higher likelihood of subsequent re-gained response, regardless of therapy escalation.Keywords
Funding Information
- Chaim Sheba Medical Center
- Leona M. and Harry B. Helmsley Charitable Trust
- Fundação para a Ciência e Tecnologia (PDE/BDE/114583/2016)
This publication has 35 references indexed in Scilit:
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY ConsortiumAmerican Journal of Gastroenterology, 2016
- Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseTherapeutic Advances in Gastroenterology, 2016
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2016
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD PatientsInflammatory Bowel Diseases, 2015
- Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysisAlimentary Pharmacology & Therapeutics, 2015
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or AdalimumabClinical Gastroenterology and Hepatology, 2015
- In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytesmAbs, 2013
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- Celiac Disease Resolution After Allogeneic Bone Marrow Transplantation is Associated with Absence of Gliadin-Specific Memory Response by Donor-Derived Intestinal T-cellsJournal of Clinical Immunology, 2013
- The α4bβ7‐integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestineClinical & Experimental Allergy, 2006